FDA Advisory Committee Votes That Efficacy Results of Cempra ' s Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia

CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news